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Conclusion

Introduction
•
•
•
•
•
•

Malaria has plagued mankind for thousands of years, claiming
2-5% of all deaths in the 20th century alone.
Half the global population lives in regions at risk of malaria
transmission. This is unsurprising given malaria is spread by
mosquitoes.
Malaria remains highly prevalent in
impoverished/infrastructurally underdeveloped regions.
These regions are particularly prone to exploitation through
counterfeiting practices.
Malaria has been largely eliminated from infrastructurally
developed countries, but remains burdensome in
underdeveloped countries due to a growing counterfeit
antimalarial industry.

•
•
•
•
•
Regions currently at risk of malaria transmission.

•

The counterfeiting industry is extremely profitable despite
counterfeit medication often costing less than authentic
medicine.
Impoverished groups remain highly vulnerable to exploitation
through counterfeiting, which perpetuates poverty levels.
Child mortality is greatly accentuated through counterfeiting.
Mutated strains of malaria extend globally, beyond just malaria
endemic regions.
Global interconnectedness threatens to rapidly spread
treatment-resistant malaria.
It is imperative that stringent punishment and harmonized
international regulations are implemented to combat this
industry.
Left unchecked, the counterfeit antimalarial industry will
continue perpetuating malaria’s existence.
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18 countries that
reported similar
falsified
medications as the
33 million bust.

•

The CDC estimates that in 2020 alone, there were 241 million cases and
627 thousand deaths attributed to malaria. 95% of the deaths occurred in
Africa.
Of this 95%, the WHO claims that children under the age of 5 accounted
for 80% of all these deaths (about 475,000 children under 5).
1 in 20 children under the age of 5 will die from malaria.
Counterfeit antimalarials cause up to an estimated 450,000 deaths per year.
33 million doses of falsified medication were seized by customs officials
during a shipment inspection from China. These falsified medicines were
all branded with a recognizable green leaf logo of quality.
Despite this seizure, the same and adjacent falsified drugs were reportedly
found circulating in 18 other neighboring countries less than a year later.
This points toward an industrially scaled counterfeiting industry.
One estimate suggests that only 20% of the 193 WHO member states have
well developed drug policies/law enforcement agencies. 50% have varying
levels and 30% have no medical regulation at all.
A French company produced and distributed 8 million doses of subpotent
antimalarials and only received a 110,000 euro fine and 2 pharmacists
received less than 2 years of prison time.
1 in 10 medicines in lower income African countries are estimated to be
substandard.
Counterfeit antimalarials have led to malaria mutations resistant to
currently working treatments.

Artemether and Lumefantrine is a commonly reported falsified
antimalarial medication with the green leaf logo of quality.

Coartem is another commonly falsified antimalarial
medication circulating with the green leaf logo.

